Ambrx Biopharma Inc. AMAM NYSE

Ambrx Biopharma Inc. (AMAM) generated $-68.68M in operating cash flow for fiscal year 2022. After capital expenditures of $1.05M, free cash flow was $-69.73M.

Free cash flow margin was -942% of revenue. Cash conversion ratio was 0.88x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (58/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (10/100) — Cash conversion ratio was 0.88x suggests some earnings are non-cash items

Overall SharesGrow Score: 28/100 with 0/7 criteria passed.